Independent fund research. Built on SEC filings.

How we research funds

Mutual fund · Large Value · Manning & Napier

Disciplined Value Series Class Z (MDVZX)

Ticker MDVZX · · Holdings as of Jul 31, 2026

Expense ratio
0.4%$40/yr per $10k
5-yr return
+10.0%annualized
1-yr return
+16.1%as of Dec 2025
Net assets
$130.8Mall share classes
Holdings
127

Bottom line

Is MDVZX a good fund? The bottom line

MDVZX is the Class Z share class of Disciplined Value Series, an actively managed large value mutual fund from Manning & Napier.

Annual fees run 0.4% — about $40 a year on every $10,000 invested, cheaper than 87% of large value funds we track.

It returned +16.1% over one year, +10.0% a year over five years, +10.9% a year over ten (as of Dec 31, 2025, per its prospectus).

With $131 million in net assets and 127 holdings, its largest position is Merck & Company Inc (3.8%) and the top 10 make up 25.6% of the portfolio.

What stands out

  • Low cost: cheaper than 87% of large value peers

Updated Nov 19, 2026

What MDVZX invests in

To provide competitive returns consistent with the broad equity market while also providing a level of capital protection during market downturns.

The Series will, under normal circumstances, invest at least 80% of its assets in dividend-paying common stocks. The Series principally invests in the common stocks of mid- to large- capitalization companies. The Advisor constructs a portfolio consisting primarily of U.S. companies trading on U.S. stock exchanges that it believes will provide competitive returns consistent with the broad equity market while also providing a level of capital protection during sustained market downturns. In selecting securities for the Series, the Advisor uses a systematic process to identify stocks of companies that it believes are undervalued in the market, based on factors such as free cash flow generation and earnings power, and that meet other investment criteria relating to minimum dividend yield, dividend sustainability, and financial health. The Series investment strategy may involve allocating…

From the fund's prospectus (filed Mar 2, 2026).

MDVZX performance

Average annual total returns
1 yr5 yr10 yr
MDVZX+16.1%+10.0%+10.9%
Large Value median+13.6%+11.3%+10.2%

Source: Fund prospectus, as of Dec 31, 2025

Full MDVZX performance history →

What MDVZX costs

On a $10,000 investment, MDVZX's 0.4% expense ratio costs about $40 a year. The prospectus estimates $578 in total costs over 10 years (assuming 5% annual returns). The median large value fund charges 0.81%.

See the full MDVZX fee table →

MDVZX top 10 holdings

#Holding% of fund
1Merck & Company Inc MRK3.83%
2Citigroup Inc C3.48%
3Unitedhealth Group Inc UNH2.79%
4Wells Fargo & Company WFC2.55%
5Gilead Sciences Inc GILD2.50%
6Conocophillips COP2.37%
7Bristol-myers Squibb Company BMY2.25%
8Exxonmobil Holdings Corp XOM2.01%
9Qualcomm Inc QCOM1.97%
10US Bancorp USB1.87%

Source: SEC Form N-PORT, period ended Jul 31, 2026

The top 10 make up 25.6% of the fund. See all top 25 holdings and asset mix →

Alternatives to MDVZX

More funds like MDVZX →

MDVZX FAQ

What is the expense ratio of MDVZX?
MDVZX's expense ratio is 0.4%, which works out to about $40 a year for every $10,000 invested. The prospectus estimates total costs of $578 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is MDVZX a good investment?
It depends on your goals, but the data points to: low cost: cheaper than 87% of large value peers. This is general information, not personalized advice.
What does MDVZX hold?
MDVZX's largest holdings are Merck & Company Inc (3.8%), Citigroup Inc (3.5%), Unitedhealth Group Inc (2.8%), Wells Fargo & Company (2.5%), Gilead Sciences Inc (2.5%). It holds 127 positions in total as of Jul 31, 2026 (SEC Form N-PORT).
What is MDVZX's 5-year return?
MDVZX returned +10.0% a year over the five years ending Dec 31, 2025, and +10.9% a year over ten years. Past performance does not guarantee future results.
Who manages MDVZX?
MDVZX is offered by Manning & Napier through Manning & Napier Fund, Inc..